Every material Form 8-K Cadrenal Therapeutics, Inc. has filed with the SEC since August 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cadrenal Therapeutics said its Board of Directors has authorized a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio, including licensing, asset sales, partnerships, portfolio transactions, or business combinations. The company describes the review as preliminary, with no set deadline and no assurance it will lead to any transaction, and it does not plan to update shareholders until the Board approves a specific transaction or disclosure is otherwise required.
The Board authorized the strategic process, announced in a press release dated October 7, 2026.
Tungsten Advisors is engaged as the company's exclusive strategic financial adviser.
The review covers CAD-1005, tecarfarin, frunexian, and CAD-2000.
No deadline or definitive timetable has been set, and the company will not provide updates unless a specific transaction is approved or disclosure is required.
At its September 24, 2026 annual meeting, Cadrenal Therapeutics stockholders approved Amendment No. 2, which raises the share reserve under the 2022 Successor Equity Incentive Plan to 1,000,000 shares. They also approved issuing up to 960,000 shares on exercise of Series C-1 warrants from a private placement that closed July 1, 2026. The added share capacity and potential warrant shares could dilute existing holders' stakes.
Plan amendment increases the 2022 Plan share reserve by 323,542 shares to 1,000,000 shares; 694,746 votes for and 352,409 against.
Stockholders approved issuing up to 960,000 shares on exercise of Series C-1 warrants; 1,011,206 votes for and 34,449 against.
Quang X. Pham was re-elected as a Class I director to serve until the 2029 annual meeting, with 1,039,666 votes for and 14,342 withheld.
WithumSmith+Brown, P.C. was ratified as independent auditor for the fiscal year ending December 31, 2026, with 2,110,693 votes for and 39,121 against.
Cadrenal Therapeutics said that at a Type D meeting with the U.S. Food and Drug Administration held July 28, 2026, the company and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005 in heparin-induced thrombocytopenia (HIT). The filing says the agreement sets the primary endpoint definition and the use of a placebo control, which the company says clarifies the regulatory path, but it does not disclose financial results, costs, or a trial start date.
Type D meeting with the FDA held July 28, 2026; the company announced the feedback on August 31, 2026.
Primary endpoint measures the proportion of Serotonin Release Assay-positive participants with adjudicated new or worsening composite thromboembolic events through Day 14 or hospital discharge.
The FDA agreed to a placebo control, with standard anticoagulation therapeutics in both the CAD-1005 and placebo arms.
The company states that approximately 50,000 patients in the U.S. have acute HIT each year.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cadrenal Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →